181
Participants
Start Date
September 19, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Abrysvo
A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
Beyfortus
A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
Vanderbilt University Medical Center, Nashville
Emory University School of Medicine, Atlanta
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
New York University School of Medicine - Langone Medical Center - Vaccine Center, New York
University of Rochester Medical Center - Vaccine Research Unit, Rochester
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh
Baylor College of Medicine, Houston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH